Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
11 evidence topics · 6 sources
Preclinical pharmacology of the dual agonist series: diet-induced obese mice compared with semaglutide
Preclinical pharmacology of the dual agonist series: diet-induced obese mice compared with tirzepatide
Preclinical pharmacology: 8-week weight change in obese primates compared with tirzepatide
Subcutaneous formulation: liver fat after four weekly doses in the phase 1 multiple ascending dose study
Subcutaneous formulation: plasma lipids in the phase 1 multiple ascending dose study
Subcutaneous formulation: glycemic status and lipids at week 13 in the phase 2 trial
“Of the 74 participants who had prediabetes at baseline, 58 (78%) shifted to normoglycemic at Week 13 in the active treatment groups and none shifted from prediabetes to diabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lipid markers generally declined over the 13‐week study in the active treatment group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only total cholesterol had a p value less than 0.05 versus placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: fasting glucose, HbA1c, and blood pressure at week 13 in the phase 2 trial
Subcutaneous formulation: weight loss persisting after the last dose in the phase 2 trial
Subcutaneous formulation: maximal effect not reached in 13 weeks
Oral formulation: satiety and appetite in the phase 1 multiple ascending dose study
Oral formulation: weight loss persisting after the last dose and with every-other-day dosing
Gastric emptying, energy intake, and body composition in humans
No evidence found.